Dr. Lorch on the Treatment of Medullary Thyroid Cancer

Jochen H. Lorch, MD
Published: Wednesday, Mar 29, 2017



Jochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.

Less than 4% of all thyroid cancers are medullary thyroid cancer. Although many cases of this disease are stable and do not require treatment for many years, eventually patients can enter into an accelerated phase which requires systemic treatment, Lorch says.

Currently, there are 2 FDA-approved drugs for medullary thyroid cancer that progresses beyond the initial treatment of surgery and surveillance, vandetanib (Caprelsa) and cabozantinib (Cometriq).
 


Jochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.

Less than 4% of all thyroid cancers are medullary thyroid cancer. Although many cases of this disease are stable and do not require treatment for many years, eventually patients can enter into an accelerated phase which requires systemic treatment, Lorch says.

Currently, there are 2 FDA-approved drugs for medullary thyroid cancer that progresses beyond the initial treatment of surgery and surveillance, vandetanib (Caprelsa) and cabozantinib (Cometriq).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x